Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$4.82
+4.8%
$5.13
$4.02
$9.33
$1.15B0.814.38 million shs5.06 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$8.44
+4.2%
$10.26
$8.02
$18.80
$4.19B1.444.92 million shs5.41 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$30.65
+5.3%
$60.72
$27.66
$121.06
$3.95B1.261.22 million shs1.72 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$61.74
+0.7%
$54.70
$35.17
$68.58
$3.90B2.32542,891 shs628,803 shs
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ardelyx, Inc. stock logo
ARDX
Ardelyx
+4.78%+13.41%-9.40%-3.79%-26.41%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+3.73%-2.98%-21.92%-29.78%-37.03%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+5.25%+9.31%-58.98%-64.07%-50.91%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+0.65%+6.76%+18.07%+13.20%+60.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.3384 of 5 stars
4.51.00.04.42.82.50.6
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
4.3376 of 5 stars
4.23.00.00.32.43.31.9
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.2704 of 5 stars
4.62.00.00.03.92.50.0
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.9116 of 5 stars
3.52.00.04.33.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.00
Buy$10.61120.15% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$14.6773.69% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50345.35% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.00
Buy$74.9221.35% Upside

Current Analyst Ratings Breakdown

Latest ARDX, ELAN, PCVX, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/14/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $13.00
4/8/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
4/8/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
4/8/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$81.00 ➝ $92.00
4/8/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00 ➝ $80.00
4/7/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$80.00 ➝ $91.00
4/7/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$63.00 ➝ $63.00
4/1/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$138.00 ➝ $100.00
4/1/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$157.00 ➝ $137.00
4/1/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$140.00 ➝ $90.00
3/31/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$333.62M3.44N/AN/A$0.73 per share6.60
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B0.94$1.74 per share4.84$12.63 per share0.67
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$13.04 per shareN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$130.13M30.00N/AN/A$2.87 per share21.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.16N/A15.55N/A-11.73%-24.87%-10.51%5/1/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.6721.119.492.504.60%6.78%3.03%5/7/2025 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$402.27M-$3.80N/AN/AN/AN/A-23.53%-22.20%5/6/2025 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$184.68M-$4.35N/AN/AN/A-230.07%-367.36%-77.47%5/6/2025 (Estimated)

Latest ARDX, ELAN, PCVX, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02N/AN/AN/AN/AN/A
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31N/AN/AN/A$1.17 billionN/A
5/6/2025Q1 2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.67N/AN/AN/A$40.43 millionN/A
5/1/2025Q1 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.10N/AN/AN/A$79.40 millionN/A
2/26/2025Q4 2024
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 million
2/25/2025Q4 2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.15$0.14-$0.01-$0.02$1.01 billion$1.02 billion
2/25/2025Q4 2024
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.16-$1.02+$0.14-$1.02N/AN/A
2/20/2025Q4 2024
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$0.02$0.02N/A$0.02$111.16 million$116.13 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ardelyx, Inc. stock logo
ARDX
Ardelyx
0.87
4.58
4.31
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.88
17.88
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.49
3.34

Institutional Ownership

CompanyInstitutional Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
5.90%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.57%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90238.36 million222.88 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.46 million491.54 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160128.76 million120.77 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14063.22 million58.02 millionOptionable

Recent News About These Companies

Rhythm Pharmaceuticals, Inc. stock logo
Needham & Company LLC Predicts RYTM FY2027 Earnings
RYTM Q2 EPS Estimate Lifted by Needham & Company LLC
Rhythm Pharmaceuticals price target raised to $68 from $63 at BofA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$4.82 +0.22 (+4.78%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$4.86 +0.04 (+0.83%)
As of 04/17/2025 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$8.44 +0.34 (+4.25%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$8.47 +0.03 (+0.31%)
As of 04/17/2025 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$30.65 +1.53 (+5.25%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$30.78 +0.14 (+0.44%)
As of 04/17/2025 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$61.74 +0.40 (+0.65%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$61.94 +0.20 (+0.32%)
As of 04/17/2025 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.